Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today proudly announces AcrySof IQ Vivity and Clareon Vivity extended depth of focus (EDOF) intraocular lens (IOL) has surpassed more than one million implants worldwide. Vivity is the most implanted EDOF IOL globally.^1* Alcon is the global leader in IOLs—every four seconds an eye is implanted with an Alcon IOL—and continues to innovate in this space to address patients’ unmet needs.^5¤

“Reaching the one million milestone for Vivity, the world's leading EDOF IOL, represents a meaningful achievement in restoring distance, intermediate and functional near vision for people worldwide, enabling them to get back to doing and seeing the things they love,” said Mark Newson, Country Business Unit Head, Surgical Division at Alcon Canada. “Vivity offers patients who want less dependency on glasses a game-changing option with its monofocal visual disturbance profile, embodying our commitment to helping people live and see brilliantly.”

Vivity uses Alcon’s proprietary non-diffractive Wavefront-Shaping X-WAVE^TM technology, an advanced optical principal that simultaneously stretches and shifts light without splitting it—balancing quality of vision and maximizing range of vision.^2,3 This unique mechanism of action is not refractive, does not introduce spherical aberrations and has ultimately expanded PCIOL access to even more patients.

Recent, large-scale real-world data underscores the impact of Vivity on patients across the globe. The Vivity Registry Study⁴⁺ demonstrates high patient satisfaction among several patient cohorts, as the vast majority of patients (92%) report they are satisfied with their sight^∞ and three-quarters of patients report no difficulty with their sight for everyday activities.^‡ With Vivity, more than 91% of patients report no halos, glares, or starbursts.^† Additionally, nearly 50% of patients no longer need glasses for near activities; this percentage increases to 66% for patients who received monovision.

Vivity is available in more than 80 countries, including Australia, Brazil, Canada, China, France, Germany, Japan, India, Italy, South Korea, Spain, U.K. and U.S. Alcon offers a family of leading IOLs designed to meet the unique vision needs of patients, including Vivity and PanOptix—the most implanted PCIOLs worldwide—as well as Monofocal and Toric options. PanOptix surpassed 1M implants in early 2022, and is the most implanted trifocal worldwide.^5,6 For more information, please visit www.alcon.ca.